We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




China and India Challenge Pharmaceutical Giants to Improve their Healthcare Systems

By LabMedica International staff writers
Posted on 10 Sep 2012
Print article
Mature pharmaceutical markets such as the United States and the European Union (EU) countries are showing comparatively little change, in contrast to the quickly evolving healthcare markets of large emerging nations, China and India, according to a new market report.

The new report, published by healthcare market research company, GlobalData (London, UK), examined the extreme regulatory changes and economic growth experienced by these two countries that are bringing increased access to drugs and healthcare services for millions of citizens.

Recently, China has successfully transformed itself into the world’s second largest economy. China’s current five-year plan, setting policy for 2011-2015, was crafted with the goal of boosting research and development, especially in the biomedical sector, and reducing social inequality. The Chinese government is implementing a series of healthcare reforms, such as extending basic medical insurance coverage to cover 90% of the urban and rural population, and establishing an essential drug supply system to develop a unified distribution network. The plan to build 29,000 township hospitals, resulting in one hospital for each county, is to be met by the free training of general practitioners (GPs) and the recruitment of new doctors for rural areas.

India’s recent healthcare policies reflect China’s aim of caring for the country’s increasing population, by allowing billions of people to gain access to healthcare for the first time. In early March 2012, Prime Minister Manmohan Singh, who once described the country’s healthcare system as a “national shame,” announced plans for a massive increase in spending on healthcare. India now lags behind other developing countries in terms of healthcare outcomes, with a shockingly high rate of infant mortality and a 40% rate of child malnourishment. If the country is to build upon its recent economic gains, it must improve its healthcare system. India, similar to China, plans to invest in medical staff training, with a goal of opening 600 medical schools and 1,500 nursing colleges to train over one million doctors and 2.5 million nurses in an effort to lessen the country’s shortage of caregivers.

China and India have populations numbering billions, yet pharmaceutical pricing pressures are set to increase, and may foil the efforts of global companies to profit greatly from this potential moneymaker. The regulation of drug pricing represents a growing trend, with India granting its first compulsory license in March 2012, allowing local generics manufacturers to produce a generic version of Bayer’s patented cancer drug, Nexavar, in spite of intellectual property protections. Although China has not yet granted any compulsory licenses, it has announced an intention to do so in the future.

The reassurance of compulsory licensing presents a material risk to pharmaceutical drug sales, with Roche already taking preemptive steps to introduce less expensive versions of specific drugs in an attempt to control the abuse of their patents. GlobalData’s senior analyst for healthcare industry dynamics, Michael Leibfried, stated that, “the oncology giant has announced it will introduce cheaper, differently branded versions of certain drugs in India--preempting the issuance of compulsory licenses and could serve as a deterrent against the exportation of these drugs to markets that are more lucrative.”

Only the future will reveal whether these emerging countries will allow intellectual property to be upheld, or whether their goal for cost-effective public healthcare will challenge more laws and stymie corporate investment.

Related Links:

GlobalData



Gold Member
Blood Gas Analyzer
GEM Premier 7000 with iQM3
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Newborn Screening Test
NeoMass AAAC 3.0
New
FLU/RSV Test
Humasis FLU/RSV Combo

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.